Furosemide


Generic Medicine Info
Administration
May be taken with or without food. May be taken w/ meals to reduce GI discomfort.
Contraindications
Hypersensitivity to furosemide and sulfonamides. Anuria, renal failure with anuria not responding to furosemide; renal failure due to poisoning by nephrotoxic or hepatotoxic agents; renal failure associated with hepatic coma, electrolyte disturbances (e.g. severe hyponatraemia, severe hypokalaemia), hypovolaemia, dehydration, hypotension; comatose or pre-comatose states associated with liver cirrhosis or encephalopathy; Addison's disease, porphyria, digitalis intoxication. Lactation.
Special Precautions
Patient with prediabetes or diabetes mellitus; prostatic hyperplasia, urinary stricture, impaired micturition, gout, hepatorenal syndrome, hypoproteinaemia (e.g. nephrotic syndrome), cirrhosis, acute hypercalcaemia; at risk from a pronounced fall in blood pressure (e.g. significant coronary or cerebral artery stenosis). Not recommended in patients at high risk for radiocontrast nephropathy. Renal and hepatic impairment. Children and elderly. Pregnancy. Patient Counselling This drug may cause reduced mental alertness, dizziness, and blurred vision, if affected, do not drive or operate machinery. Monitoring Parameters Correct hypovolaemia, hypotension, and severe electrolyte disturbances prior to treatment initiation. Monitor blood pressure, serum electrolytes (e.g. serum Na, K), renal function, and blood glucose levels periodically; orthostasis, hearing (on high doses or rapid IV administration).
Adverse Reactions
Significant: Fluid and electrolyte depletion, symptomatic hypotension, asymptomatic hyperuricaemia, nephrotoxicity, ototoxicity (e.g. hearing disorders, tinnitus, deafness [sometimes irreversible]), photosensitivity, sulfonamide allergy, urinary retention, SLE exacerbation or activation; nephrocalcinosis or nephrolithiasis (in premature infants), decreased glucose tolerance, transient increase in free thyroid hormones. Blood and lymphatic system disorders: Haemoconcentration. Rarely, agranulocytosis, thrombocytopenia, leucopenia. Eye disorders: Blurred vision. Gastrointestinal disorders: Nausea, vomiting, diarrhoea, constipation. General disorders and administration site conditions: Fatigue, pain at inj site (IM). Investigations: Increased creatinine, serum cholesterol and triglycerides; increased blood urea and urine volume. Immune system disorders: Rarely, severe anaphylactic or anaphylactoid reactions. Metabolism and nutrition disorders: Dehydration, hyponatraemia, hypokalaemia, hypochloraemia, metabolic alkalosis, hypocalcaemia, hypomagnesaemia, hypovolaemia, gout. Musculoskeletal and connective tissue disorders: Muscle spasms. Nervous system disorders: Headache, dizziness, hepatic encephalopathy (in patient with hepatic insufficiency), paraesthesia. Skin and subcutaneous tissue disorders: Rash, pruritus, urticaria, erythema multiforme. Vascular disorders: Orthostatic hypotension.
Drug Interactions
Increased risk of hyperkalaemia with K-sparing diuretics (e.g. amiloride, spironolactone) and K salts. Diuretic effects may be antagonised by NSAIDs (e.g. indometacin, ketorolac), and reduced by phenytoin, probenecid, methotrexate. May cause severe hypotension with ACE inhibitors or angiotensin II receptor antagonists. Increased risk of cardiotoxicity with cardiac glycosides, antihistamines, antipsychotics (e.g. pimozide, risperidone). May enhance the nephrotoxic effects of aminoglycosides, cisplatin, cephalosporins. May increase the risk of ototoxicity with aminoglycosides, polymyxin, vancomycin, cisplatin, ethacrynic acid, and other ototoxic drugs. Reduced serum level with aliskiren. May increase the serum levels of lithium. May antagonise the hypoglycaemic effects of antidiabetics. Enhanced hypotensive effect with MAOIs. Increased risk of hyponatraemia with carbamazepine. Gastrointestinal absorption may be decreased by sucralfate. May potentiate the effects of salicylates causing toxicity. Increased risk of gouty arthritis with ciclosporin.
CIMS Class
Diuretics
ATC Classification
C03CA01 - furosemide ; Belongs to the class of high-ceiling sulfonamide diuretics.
Disclaimer: This information is independently developed by CIMS based on furosemide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in